



# The clinical diagnosis of Parkinson's disease

## *O diagnóstico clínico da doença de Parkinson*

Renato P. Munhoz<sup>1,2</sup>  Vitor Tumas<sup>3</sup>  José Luiz Pedrosa<sup>4</sup>  Laura Silveira-Moriyama<sup>5,6</sup> 

<sup>1</sup> University Health Network, Toronto Western Hospital, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto, ON, Canada.

<sup>2</sup> Krembil Research Institute, Toronto, ON, M5T 2S8, Canada.

<sup>3</sup> Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil.

<sup>4</sup> Universidade Federal de São Paulo, Departamento de Neurologia, São Paulo SP, Brazil.

<sup>5</sup> Universidade Estadual de Campinas, Campinas SP, Brazil.

<sup>6</sup> UCL Queen Square Institute of Neurology, London, United Kingdom.

Address for correspondence Renato P. Munhoz (email: renato.munhoz@uhn.ca)

Arq. Neuropsiquiatr. 2024;82(6):s00431777775.

### Abstract

#### Keywords

- ▶ Parkinson Disease
- ▶ Supranuclear Palsy, Progressive
- ▶ Multiple System Atrophy
- ▶ Atherosclerotic Parkinsonism
- ▶ Secondary Parkinsonism

After more than 200 years since its initial description, the clinical diagnosis of Parkinson's disease (PD) remains an often-challenging endeavor, with broad implications that are fundamental for clinical management. Despite major developments in understanding its pathogenesis, pathological landmarks, non-motor features and potential paraclinical clues, the most accepted diagnostic criteria remain solidly based on a combination of clinical signs. Here, we review this process, discussing its history, clinical criteria, differential diagnoses, ancillary diagnostic testing, and the role of non-motor and pre-motor signs and symptoms.

### Resumo

#### Palavras-chave

- ▶ Doença de Parkinson
- ▶ Paralisia Supranuclear Progressiva
- ▶ Atrofia de Múltiplos Sistemas
- ▶ Parkinsonismo Secundário
- ▶ Parkinsonismo Aterosclerótico

Passados mais de 200 anos desde a sua descrição inicial, o diagnóstico clínico da doença de Parkinson (DP) continua a ser um processo muitas vezes desafiante, com amplas implicações que são fundamentais para o manejo clínico. Apesar dos grandes desenvolvimentos na compreensão da sua patogênese, marcadores patológicos, características não motoras e potenciais pistas paraclínicas, os critérios diagnósticos mais aceitos permanecem solidamente baseados numa combinação de sinais clínicos motores. Aqui, revisamos esse processo, discutindo sua história, critérios clínicos, diagnósticos diferenciais, testes diagnósticos complementares e o papel dos sinais e sintomas não motores e pré-motores.

received  
September 14, 2023  
received in its final form  
November 08, 2023  
accepted  
November 19, 2023

DOI <https://doi.org/10.1055/s-0043-1777775>.  
ISSN 0004-282X.

© 2024. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (<https://creativecommons.org/licenses/by/4.0/>).

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

## INTRODUCTION

In 1817 James Parkinson described the clinical characteristics of 6 patients who had a neurological syndrome that had not yet been well characterized, which he called "paralysis agitans" or "shaking palsy"<sup>1</sup>. In his observations, Parkinson captured main clinical features such as the insidious onset with a progressive disabling course, the presence of resting tremors with asymmetrical body involvement, postural changes with flexion of the trunk, neck, and limbs, abnormal gait with festination, presence of dysarthria, dysphagia, and drooling. He also described the presence of constipation and cognitive preservation.

The description of this new syndrome was slowly incorporated into the medical literature of that period, and at the end of the 19th century, two authors made important contributions.<sup>2-4</sup> Trousseau described the presence of muscular rigidity and the progressive slowing of repetitive movements, also noting that patients developed cognitive decline as the condition progressed. Charcot defined bradykinesia as one of the most important manifestations of the disease and the main source of motor disability. He suggested the eponym Parkinson's disease (PD) celebrating the original descriptor. Charcot also noted that there were clinical variants of this syndrome with atypical presentations without tremor, with extension rigidity, with hemiplegia, and "astonished face".

At the beginning of the 20th century, between 1917 and 1926, the encephalitis lethargica pandemic left post-encephalitic parkinsonism as a sequelae, which was the first recognized secondary cause of parkinsonism. At that time, authors like Critchley tried to characterize various Parkinson-like syndromes, such as "atherosclerotic parkinsonism", already recognizing the heterogeneity of the syndrome and its probable etiologies.<sup>4</sup> Besides, studies by many authors including Lewy, Tretiakoff, Marinesco, Foix, and Nicolesco made it possible to determine that alterations in the substantia nigra compacta and the presence of Lewy bodies (LBs) were the essential pathological substrate of PD.

In 1967, Hoehn and Yahr wrote their seminal study on parkinsonism in the pre-levodopa era.<sup>5</sup> They described the clinical characteristics of 802 patients with "*all of the accepted cardinal signs of parkinsonism: rest tremor, plastic rigidity, paucity or delayed initiation of movement, slowness, and impaired postural and righting reflexes*". PD was defined as the primary or "idiopathic" form of the disease. The suspicion of an underlying process that could be considered etiologic in inducing the clinical signs, or the presence of associated or atypical neurologic abnormalities, excluded a given case from this idiopathic diagnostic category. The authors defined secondary parkinsonism when the syndrome was linked to a potential etiologic agent and/or there were signs suggesting that parkinsonism was part of a pathologically broader disease affecting systems not typically involved in the archetypal syndrome. These secondary cases were classified as postencephalitic parkinsonism or "others". Finally, a certain proportion of cases were classified as having indeterminate parkinsonism, as they were deemed impossible to determine whether the clinical signs were primary

or secondary. As such, the possibility of different causes for parkinsonism was already well recognized and the differential diagnosis was based on the clinician's impressions.

At that time, it was already not infrequently acknowledged that the diagnosis of PD could be challenging and mistaken for aging-related gait alterations, mobility limitations secondary to joint abnormalities, and especially for cases of essential tremor and neuroleptic-induced parkinsonism. Concurrently, the degenerative diseases that would later be considered the main causes of atypical parkinsonism are very well described [multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)].<sup>6-8</sup> Also in the 1960s, studies showed that LBs, characteristic of PD, could be found in the brains of elderly people who died asymptomatic or who had discreet and dubious signs of parkinsonism.<sup>9,10</sup> These observations led to the hypothesis that there was a prodromal phase preceding the appearance of the typical signs of PD. It would later become clear that there must be significant neuronal loss in the substantia nigra compacta and severe striatal depletion of dopamine for the signs of parkinsonism to surface.<sup>11</sup>

In the 1970s, the therapeutic revolution in this field began with the use of levodopa. It soon became clear that some patients diagnosed with PD did not respond to treatment, and that it was common for many to develop levodopa-induced dyskinesias.<sup>12</sup> In the 1980s, the term Parkinson-plus began to be used to designate cases of parkinsonism with a supposed neurodegenerative etiology that "mimics PD" added by additional or atypical clinical features such as cerebellar or pyramidal signs.<sup>13</sup> At this time, clinical-pathological studies carried out in the UK by Gibb and Lees outlined for the first time the clinical characteristics that best distinguished PD from other pathologic conditions that also cause parkinsonism.<sup>14,15</sup> These studies also gave rise to the first well-defined diagnostic criteria for PD, discussed next.

## DIAGNOSTIC CRITERIA

The diagnosis of PD has evolved considerably over the last decades. One of the main advances was the furthering of the understanding of differential diagnoses, with the description of MSA<sup>16</sup> and PSP<sup>8</sup> in the 1960s. The next decades of literature were marked by better delineation of the clinical features of PD which could lead to higher diagnostic accuracy and the seminal paper from Gibb and Lees<sup>10</sup>, which is cited as the original source of the Queen Square Brain Bank (QSBB) Criteria for the diagnosis of PD. The manuscript looked at the age-specific prevalence of LBs in the brains of 273 individuals who did not suffer from PD, showing a growing proportion of brains positive for the inclusion from 3.8% to 12.8% between the sixth and ninth decades. The "UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria" (later renamed QSBB Criteria) is mentioned in the introduction and described in detail in a table describing the diagnostic process for PD. Step 1 consists of identification of Parkinsonian syndrome. Bradykinesia is an obligatory criterion for

the syndrome, and it is defined as “slowness of initiation of voluntary movement, with a progressive reduction in speed and amplitude of repetitive actions”. This definition of bradykinesia was a powerful ally in differentiating bradykinesia from slowness in other conditions such as dystonia, altered mental states, depression, etc. Step 2 was the exclusion of findings that could point to alternative diagnoses including findings in history (stepwise decline, repeated head trauma, encephalitis, or treatment with dopamine receptor blocking agents at onset), neurological examination (oculogyric crises, supranuclear gaze palsy, cerebellar signs, Babinski signs) or disease course (early severe dysautonomia or dementia, unilateral disease after 3 years). And finally, Step 3 was the presence of supportive criteria. The QSBB Criteria proposes the following features as supportive criteria: occurrence of rest tremor, unilateral onset with ongoing asymmetry, evidence of progression, consistent levodopa response (>70%), levodopa-induced chorea, levodopa response for more than 5 years, long clinical course (>10 years).<sup>10</sup>

The QSBB Criteria became the most widely used criteria for the diagnosis of PD in the subsequent years, and by the 1990s the clinical accuracy of the diagnosis of PD had significantly increased to up to 90% in the hands of special-

ists.<sup>17</sup> Slowly small changes were made to the criteria, including ignoring the exclusion of hereditary cases, since it became clear that certain genetic disorders including mutations in alpha-synuclein<sup>18</sup> and in LRRK2<sup>19,20</sup> could cause a form of PD that could be clinically identical to idiopathic PD both from the clinical point of view and the neuropathological as well since both presented with LBs and Lewy neurites with alpha-synuclein accumulation.<sup>21</sup> The advent of ancillary tests which could show abnormalities in PD cases started to be incorporated into clinical practice, mainly the use of olfactory tests,<sup>22</sup> cardiac imaging using MIBG,<sup>23</sup> and functional imaging of the dopaminergic pathways.<sup>24</sup> With the growing interest in scientific studies in PD it also became important to include different levels of certainty on the diagnosis, enabling better diagnostic certainty using criteria with high specificity for recruitment in clinical studies and empirical management in daily practice. In 2015 The International Parkinson and Movement Disorder Society (MDS) created a new set of criteria, to include these concepts and further improve the accuracy of the diagnosis.<sup>25</sup> The QSBB and the new MDS criteria are compared in **Table 1**. The central part of the diagnosis did not change significantly, but two different diagnostic categories were created: Clinically Established PD and Clinically Probable PD.

**Table 1** Comparison of the QSBB and the new MDS criteria.

Criteria	Queen Square Brain Bank Criteria (Gibb & Lees, 1988) <sup>10</sup>	MDS criteria for Parkinson's disease (Postuma et al., 2015) <sup>25</sup>
Chore findings	STEP 1: identification of Parkinsonian syndrome. Defined as bradykinesia and at least one of the following: <ul style="list-style-type: none"> <li>• Muscular rigidity.</li> <li>• 4-6 Hz rest tremor.</li> <li>• Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction.</li> </ul>	The first essential criterion is parkinsonism, which is defined as bradykinesia, in combination with at least 1 of rest tremor or rigidity.
Negative features used as	Step 2: Exclusion Criteria	Absolute exclusion criteria or Red flags (when combined with supportive criteria do not exclude PD)
Positive features used as	Step 3: Supportive Criteria	Supportive Criteria
Ancillary tests	Imaging used to exclude differential diagnosis (Step 2)	Olfactory loss or cardiac sympathetic denervation on MIBG scintigraphy are supportive criteria Normal functional neuroimaging of the presynaptic dopaminergic system is an exclusion criteria
Certainty levels	Definite PD (three or more positive supportive findings)	Clinically Established PD: 1. Absence of absolute exclusion criteria 2. At least two supportive criteria, and 3. No red flags Clinically Probable PD: 1. Absence of absolute exclusion criteria 2. Presence of red flags counterbalanced by supportive criteria - 1 red flag requires at least 1 supportive criterion - 2 red flags require at least 2 supportive criteria - no more than 2 red flags are allowed for this category

The first level uses criteria for higher specificity, while the second tries to achieve a balance between sensitivity and specificity, to include a larger number of PD cases (that would not make the cut for clinically established) without including too many false positives. In addition, the MDS also created derivative criteria to be applied to early disease when diagnosis is more challenging, mainly for the purpose of clinical trials.<sup>26</sup>

## DIFFERENTIAL DIAGNOSIS OF PARKINSON'S DISEASE

The hypernym term parkinsonism refers to the concomitant finding of two or more out of four signs: bradykinesia, resting tremor, rigidity, and postural instability,<sup>27</sup> invariably including PD as the most common etiologic diagnosis. The term, however, encompasses expanding and variable subsets of disorders that conform to this criterion, including secondary forms [e.g., infectious, drug-induced (DIP), vascular parkinsonism (VP)], sporadic ["atypical parkinsonism" e.g., MSA, PSP, CBD, Lewy body dementia (LBD), etc.], and hereditodegenerative disorders [e.g., Wilson's disease (WD), Huntington's disease (HD), spinocerebellar ataxias (SCA)].<sup>28</sup> Physiopathologically, these disorders have at least one common feature: disruption of the nigrostriatal pathway, induced by chemical, structural, or, more often, degenerative abnormalities leading to flawed control of voluntary movements.<sup>17</sup> Suboptimal diagnostic accuracy, unfortunately, is not rare as noted in two important clinicopathological studies that found a matching ante- and post-mortem diagnosis in 76% of PD cases, ranging from 41 to 88% in cases with pathologic diagnosis of MSA and PSP.<sup>29–32</sup> These findings have important implications both on clinical and research grounds as a wrong final diagnosis may distort the results of epidemiological, therapeutic, and genetic studies, and misguide management and prognostic aspects related to each of these syndromes. Finally, although most of the differential diagnoses of PD have their own established diagnostic criteria, the phenotypes often overlap and they do not have objective pathognomonic clinical or paraclinical findings.<sup>29</sup>

► **Table 2** describes the main different Parkinsonian syndromes, their features, and clues for diagnosis.

## PRODROMAL PARKINSON'S DISEASE

At the moment, criteria for diagnosis of PD are based on the finding of a combination of motor symptoms and signs as previously stated in this review.<sup>27</sup> However, multiple lines of evidence unequivocally show that by the time when these features surface to clinical detection, pathological and neurochemical hallmarks of the disease are already established and have been already in progress for a considerable amount of time.<sup>33</sup> As such, the quest for a "pre-motor syndrome" delineating potential non-motor features that, alone or in combination, could have enough specificity to suggest the eventual PD diagnosis is of importance for multiple reasons, including the opportunity to contemplate interventions aimed at slowing or stopping disease progression at the

earliest pathological stages, even before nigro-striatal degenerative neuronal damage is severe enough to set off early motor dysfunction.<sup>34,35</sup> The groundwork for this endeavor, based on their clinical aspects rather than functional or pathological facets and implications, is discussed below.

## OLFACTORY DEFICITS AND HYPOSMIA

The investigation of olfactory deficits in PD dates back almost half a century,<sup>5</sup> with early observations highlighting its emergence as a potential pre-motor sign.<sup>22</sup> Over the years, research has consistently demonstrated abnormalities in odor discrimination, detection threshold, and identification in PD patients, irrespective of various clinical parameters.<sup>36,37</sup> Since then, the literature explored this topic trying to elucidate the multifaceted nature of olfactory dysfunction in PD, exploring its association with dopaminergic and cholinergic mechanisms, the presence of LBs, and its implications for early diagnosis. Current available studies span for decades, encompassing diverse patient populations in terms of age of onset, disease duration and severity, motor laterality, phenotype, treatment status, and cognitive impairment. These investigations employed methods ranging from clinical assessments of olfactory sensitivity to post-mortem examinations, aiming to unravel the intricate relationship between olfactory dysfunction and PD. Contrary to initial expectations, olfactory dysfunction in PD does not exhibit a direct correlation with dopaminergic dysfunction or the motor signs characteristic of the disease.<sup>38</sup> Instead, evidence suggests that cholinergic deficits, particularly in the limbic cortex, play a more substantial role in determining olfactory deficits in PD than nigrostriatal dopaminergic denervation. The presence of LB in the olfactory bulb emerges as a consistent pathological marker in symptomatic PD patients, occurring in virtually all cases, building upon the hypothesis proposed by Braak et al.,<sup>33</sup> which posits that the degenerative process in PD initiates in the olfactory bulb and anterior olfactory nuclei, leading to olfactory sensitivity loss in 70%-90% of PD patients, including those who are treatment-naïve and newly diagnosed.<sup>36</sup> This supports the notion that hyposmia serves as a pre-motor sign, with LB consistently found in the substantia nigra pars compacta (SNc) alongside these pathological markers in olfactory structures. However, the temporal relationship between the onset of hyposmia and the manifestation of motor signs remains uncertain, with a potential lag of several years.<sup>39</sup>

In summary, olfactory dysfunction in PD presents a complex interplay of neurobiological factors involving dopaminergic and cholinergic systems, as well as the presence of LB in specific areas. Understanding the nuances of olfactory deficits not only contributes to the elucidation of PD's pathophysiology but also offers valuable insights for early diagnosis. Moreover, the distinct patterns of hyposmia observed in PD, MSA, PSP, and CBD underscores its potential utility as a diagnostic marker in differentiating Parkinsonian syndromes. Further research is warranted to unravel the temporal dynamics of olfactory dysfunction and its role in the prodromal phase of PD.<sup>39</sup>

**Table 2** Clinical features of the most common differential diagnoses of the syndrome.<sup>27–32</sup>

	PD	DIP	VP	PSP	MSA-P	LBD	CBD
Mean age of onset (SD)	59.4 (11.5)	60.6 (13.4)	70.6 (6.4)	66.9 (7.6)	55.5 (6.5)	67.8 (9.2)	63 (7.7)
Tremor	Pure rest (30%), pure action (20%), mixed (20%)	Pure rest (35%), pure action (10%), mixed (30%)	Pure rest (4%), pure action (10%), mixed (2%)	Pure rest (10%) <sup>a</sup> , pure action (20%), mixed (20%)	Rest (5%), Action (80%) <sup>f</sup> , mixed (10%) <sup>f</sup>	Pure rest (3%), pure action (7%), mixed (24%)	Rest (2%), Action (10%) <sup>g</sup> , mixed (55%) <sup>g</sup>
Postural instability	Common but late feature	Rare	Prominent / early or presenting sign	Prominent / early or presenting sign	Prominent / early	Prominent / early	Prominent / early
Asymmetry	+++	0	+	0 <sup>a</sup>	+	0	+++
Survival – Mean (SD)	Variable <sup>b</sup>	N/A	8 (4.1)	8.6 (5.7)	7.5 (4)	4.1 (4.1)	8 (0.7)
Levodopa response	Marked / sustained	None to moderate <sup>c</sup>	None to moderate <sup>c</sup>	Mild to moderate <sup>d</sup>	Mild to moderate <sup>d</sup>	Mild to moderate <sup>d</sup>	Mild <sup>d</sup>
LID <sup>e</sup>	++++	0	+	+ <sup>a</sup>	++	+	+
Dementia	Common in advanced stages	0	Very common, presenting as VD	Very common, early, fast decline	Less common than PD	Part of diagnostic criteria; may fluctuate	Common, may be early, fast decline
RBD	Very common	0	0	Unusual	Very common	Very common	0
Additional clinical features	Slower progression compared to other degenerative forms.	Onset during treatment with offending drug; improvement / resolution after withdrawal.	Pyramidal and pseudo-bulbar signs; lower body predominant.	Supranuclear gaze palsy; disproportional axial (nuchal) rigidity; photophobia / blepharospasm;	Profound early dysautonomia; anterocollis; pseudo-bulbar affect; pyramidal signs.	Early well-formed visual hallucinations; neuroleptic sensitivity; dysautonomia.	Limb dystonia; apraxia; cortical sensory loss; alien limb phenomena.
Brain MRI findings	No specific findings on standard imaging.	No change	Periventricular white matter lesions, lacunar infarcts in BG, ventricular dilation.	Predominant midbrain atrophy; superior cerebellar peduncle atrophy.	Putaminal atrophy; OPCA and “hot cross bun sign” in advanced stages.	Global atrophy.	Asymmetric fronto-parietal atrophy.

Abbreviations: PD, Parkinson's disease; DIP, drug-induced parkinsonism; VP, vascular parkinsonism; PSP, progressive supranuclear palsy; MSA-P, Parkinsonian form of multiple system atrophy; LBD, Lewy body dementia; CBD, corticobasal degeneration; SD, standard deviation; LID, levodopa-induced dyskinesia; RBD, REM-sleep behavior disorder; MRI, magnetic resonance imaging; BG, basal ganglia; OPCA, olivo-ponto-cerebellar atrophy.

Notes: a) PSP-P variant presents with asymmetric features, rest tremor, levodopa response and LID; b) widely dependent on age of onset, ranging from 38 (5) years for early onset (25–39 years old) to 5 (4) for late onset ( $\geq 65$  years old); c) may be sustained in responders; d) typically in early stages, not sustained; e) in levodopa responders under long term treatment; f) jerky postural tremor / polyminimyoclonus; g) jerky action tremor / myoclonus.

### REM sleep behavior disorder

Rapid eye movement (REM) Sleep Behavior Disorder (RBD) is a distinctive parasomnia characterized by the loss of normal muscle atonia during the REM sleep phase. This phenomenon results in the enactment of dream content, often involving vocalizations and complex movements. In the context of PD, similar to hyposmia, RBD has emerged as a potential pre-motor sign, providing valuable insights into the neurodegenerative process.<sup>40</sup>

During REM sleep, intricate patterns of neuronal activation and neurotransmitter release occur in the brain stem, leading to motor inhibition and muscle atonia. RBD disrupts this normal physiological process, causing individuals to act out their dreams, sometimes resulting in sleep disturbances and injuries. This abnormality is particularly prevalent in PD patients, suggesting a unique distribution of the degenerative process in these individuals.<sup>40</sup> The gold standard for diagnosing RBD involves polysomnography, revealing

excessive muscle activity, and increased submental electromyography (EMG) density during REM sleep.<sup>41</sup> Clinically, historical data, ranging from formal criteria outlined in the Manual of Disorders of Sleep of the American Academy of Sleep Medicine<sup>42</sup> to a simple yes/no questionnaire, can aid in diagnosis.<sup>43,44</sup>

PD patients with RBD exhibit distinct clinical features, including worse postural instability and gait, suboptimal motor response to levodopa, orthostatic hypotension, visual color perception deficit, visual hallucinations, and an increased risk of developing dementia.<sup>41</sup> RBD often precedes the onset of motor symptoms in PD, with a mean interval of 1 to 12 years.<sup>41</sup> Notably, individuals with apparently idiopathic RBD face a greater than 50% chance of developing neurodegenerative diseases after 12 years of follow-up, most commonly PD, followed by LBD, Alzheimer's disease, and MSA.<sup>45</sup> While RBD is frequently associated with synucleinopathies, particularly PD, LBD, and MSA, its occurrence in atypical Parkinsonian syndromes such as PSP suggests a complex relationship between the disorder and the topographic progression of the degenerative process.<sup>46</sup> Understanding the intricacies of RBD in the context of PD contributes valuable insights into both diagnostic approaches and the underlying neurobiology of these conditions. Further research is warranted to elucidate the specific molecular and topographic factors influencing the manifestation of RBD across diverse neurodegenerative diseases.

### Mood disorders

Depression and anxiety are prevalent in PD, affecting more than a quarter of newly diagnosed cases. Studies indicate that individuals with depression are 2.2 to 3.2 times more likely to develop PD compared to healthy controls.<sup>47</sup> While the correlation is less conclusive than for other symptoms, such as hyposmia and RBD, depressive symptoms may precede motor signs, peaking around 3-6 years before a PD diagnosis.<sup>35</sup> A study involving 1,358 patients with depression found a 13.3 times higher chance of developing PD compared to controls without depression.<sup>48</sup> Another study reported a 2.95 times higher likelihood of PD occurrence in individuals with depression. In summary, current evidence considers depression as a risk factor for PD, though not necessarily a pre-motor symptom.<sup>49</sup>

### Constipation

Constipation is a common pre-motor symptom in PD, often present at diagnosis and extending over a variable period, up to 24 years before the onset of parkinsonism.<sup>35</sup> A longitudinal study with 6,790 males revealed a 2.7 times higher risk of PD in individuals with constipation. The time interval between constipation detection and PD diagnosis averaged 12 years.<sup>50</sup> Pathologically, alpha-synuclein aggregates in the peripheral autonomic system contribute to this relationship, affecting abdominal-pelvic, cardiac, and myenteric plexus.<sup>51</sup> Constipation may reflect both peripheral and central mechanisms, indicating pelvic floor dysfunction. Some individuals with constipation also exhibit LB in the central

nervous system, as well as pre-motor signs like RBD or striatal abnormalities.<sup>35,51</sup>

### Weight loss

PD patients often have a lower body mass index (BMI) compared to healthy controls, attributed to factors like dyskinesias, changes in eating habits, medication effects, and prolonged meal ingestion leading to lower energy intake.<sup>52</sup> Studies have explored physiological changes, such as altered levels of leptin, insulin-like growth factor type 1 (IGF-1), and thyroid-stimulating hormone in PD patients with weight loss.<sup>53</sup> Weight loss in PD is multifactorial and may occur before or throughout the disease stages. A prospective study showed that BMI remained stable in most patients until a variable period before motor symptoms appeared, ranging from a few months to four years.<sup>54</sup>

### Effect of pre-motor features on PD prediction

The effect of single and concomitant pre-motor features on prediction of PD: Although there is enough evidence to support the pre-motor nature of these signs and symptoms, their sensitivity and specificity are not high enough to call them generically "predictors" (RBD may be an exception to this statement though). Based on the prevalence of the manifestations in early disease, the maximal sensitivity favors hyposmia, while specificity is best for RBD. However, the combination of the two indicates a more than four-fold increase in the probability of PD on longer follow-up compared to presenting one of these features alone.<sup>55</sup>

## ANCILLARY INVESTIGATION FOR THE DIAGNOSIS OF PARKINSON'S DISEASE

As aforementioned, the diagnosis of PD is essentially performed based on clinical observation. However, several additional tests play an important role in its differential diagnosis with other movement disorders, such as essential tremor (ET) and atypical parkinsonism.<sup>27,56</sup> Also, genetic testing may add important tools for counseling regarding inheritance, prognosis, and even treatment choices.

### Neuroimaging in Parkinson's disease


Routine brain magnetic resonance imaging (MRI) is usually unremarkable in patients with PD. The value of brain MRI in this context lies in ruling out structural abnormalities, secondary causes of parkinsonism (i.e., VP and normal pressure hydrocephalus) and identifying changes often seen in atypical parkinsonism, such as MSA and PSP.<sup>57</sup>

In the realm of functional neuroimaging, different radiotracers and imaging techniques can access the dopaminergic pathway. Dopamine transporter (DAT) SPECT has largely been used as a reliable test to demonstrate *in vivo* dopaminergic dysfunction, by using <sup>99m</sup>Tc-TRODAT-1 (SPECT-TRODAT) transporter, a tracer that is reasonably costly and available. As the name implies, this technique traces presynaptic ligands and its measurement is a valuable imaging method to differentiate PD from its mimics like ET, dystonic tremor, or functional parkinsonism.<sup>57,58</sup> However, DAT

SPECT is *not* a reliable test to differentiate PD from atypical parkinsonism, since these conditions usually present with pre-synaptic dopaminergic dysfunction.<sup>59</sup> Attempted to use DAT SPECT to distinguish PD from atypical parkinsonism using measurements of tracers at the putamen and caudate are inconclusive so far.<sup>57,58</sup> SPECT-TRODAT has a higher sensitivity and specificity for measuring the decrement of DAT in PD patients when compared with other imaging techniques. **Figure 1A** shows a normal DAT SPECT from a healthy subject, while **Figure 1B** discloses a marked decrease in dopamine receptor binding in a patient with PD.


Recent techniques of brain MRI to evaluate the substantia nigra in PD have been developed, such as nigrosome and neuromelanin studies, quantitative susceptibility mapping (QSM), and visual assessment of dorsal nigral hyperintensity.<sup>60</sup> Nigrosome 1 is a region of the substantia nigra which is more densely affected in PD. The neuromelanin protocol is performed by using a T1-weighted fast spin echo sequence, while nigrosome is evaluated by T2 sequences.<sup>56,60</sup> Furthermore, nigrosome and neuromelanin evaluation may work as an *in vivo* marker for the progression of nigral degeneration from early to advanced stages of PD. Finally, neuromelanin-sensitive MRI may differentiate ET from PD, although sensibility and specificity are lower than the DAT SPECT.<sup>60</sup> **Figure 2** shows nigrosome and neuromelanin findings in healthy subjects, early stage of PD, and advanced stage of PD.

Positron emission tomography (PET) is a relatively expensive and not widely available technique, which, however, offers high sensitivity with better spatial and temporal resolution compared to other techniques. PET can assess both presynaptic [measurement of aromatic amino acid decarboxylase (AADC) activity (<sup>18</sup>F-DOPA), DAT activity and vesicular monoamine transporter (VMAT2) density (DTBZ)] and



**Figure 1** DAT SPECT with <sup>99m</sup>Tc-TRODAT-1. (A) shows a normal DAT SPECT from a healthy subject, while figure (B) discloses a marked decrease in dopamine in a patient with Parkinson's disease. This image is from the personal archive of the authors.

post-synaptic activities (i.e., <sup>11</sup>C-raclopride binding to striatal D<sub>2</sub> receptors). As such, these techniques may be useful to facilitate the differential diagnosis of PD when a mixed pre and post-synaptic degenerative form is suspected.<sup>56,61</sup>



**Figure 2** Brain MRI with nigrosome and neuromelanin findings, respectively in healthy subjects, early stage of PD and advanced stage of PD. In healthy subjects there is a clear swallow tail appearance in nigrosome imaging and hyperintense signal in the substantia nigra in the neuromelanin sensitive MRI. On the other hand, in advanced stages of PD, there is absence of the swallow tail appearance in nigrosome imaging and decrease of the hyperintensity in neuromelanin imaging. Early stage of PD presents with intermediate findings between both conditions described above. This image was kindly supplied by Dr. Victor Hugo Rocha Marussi, from Beneficência Portuguesa, São Paulo, Brazil.

The substantia nigra can also be evaluated using transcranial sonography. Around 90% of PD patients present with increased echogenicity of the substantia nigra while approximately 10% of healthy subjects and 16% of ET patients also have this finding.<sup>62</sup> Therefore, although transcranial sonography is a low-cost and noninvasive imaging technique to evaluate the dopaminergic pathway, it has less sensitivity and specificity than DAT SPECT and does not have a reliable accuracy for the diagnosis of PD.<sup>62</sup>

It is relevant to bear in mind that imaging studies are not methods to diagnose PD. Imaging methods such as DAT SPECT and MRI with nigrosome 1 are helpful in showing dopaminergic dysfunction or parkinsonism. In the absence of parkinsonism, abnormal nigrosome 1 or DAT SPECT does not mean that the individual has or will develop a degenerative parkinsonism.

### Genetic test for Parkinson's disease

The understanding of the etiology and molecular mechanisms of PD had a tremendous progress during the last two decades, especially due to the development of new genomic tests and genetic discoveries. The identification of mutations in genes such as *SNCA* ( $\alpha$ -synuclein), *LRRK2* (leucine-rich repeat kinase-2), or *GBA1* (glucocerebrosidase) has allowed a better understanding of the molecular and pathophysiological mechanisms of the hereditary forms and of PD in general.<sup>63</sup> However, although there are currently 25 genetically linked subtypes of PD, genetic testing in clinical practice (single genetic testing or Sanger; genetic panel; or exome sequencing) should only be recommended for a minority of patients presenting the following features:

- early onset PD (< 40-year-old);
- consistent family history;
- syndromic forms of parkinsonism with very early onset.<sup>64</sup>

In patients with a family history indicating autosomal dominant PD, the *LRRK2* gene should be investigated, especially in the Ashkenazi population. On the other hand, Brazilian patients with early onset or juvenile PD and suspected autosomal recessive disease, *PARK2*, or *PRKN* gene should be initially tested.<sup>64–66</sup>

### Cerebrospinal fluid (CSF)

A few potential cerebrospinal fluid (CSF) biomarkers have been investigated in patients with PD, including total  $\alpha$ -synuclein, oligomeric  $\alpha$ -synuclein, lysosomal enzyme activities, and neurofilament light chain.<sup>67</sup> However, differently from similar techniques used in Alzheimer's disease, PD CSF biomarkers for PD are not currently measured in routine clinical practice, been restricted to research protocols, for example, to investigate and determine pre-symptomatic stages in predisposed subjects.<sup>67</sup>

### Other ancillary tests

Other complementary tests could be used in the diagnostic workup of patients with suspected PD, especially when atypical forms of parkinsonism were not ruled out. For instance: cardiac scintigraphy is normal in MSA, and has

decreased binding in PD and Lewy body dementia; autonomic tests may be abnormal in early changes in MSA and late changes of PD; polysomnography may disclose RBD in alpha-synucleinopathies.<sup>6,25</sup>

In conclusion, the correct diagnosis of PD in the earlier stages and often during the course of the disease is a challenging process. Although treatment at the moment is mainly symptomatic and not disease-modifying from a pathological standpoint, accurate diagnosis remains a pivotal aspect of health care, given its implications regarding adequate approaches to therapeutic interventions and counseling regarding prognosis. This has been an ongoing concern since PD's early descriptions and several endeavors were historically fruitful in advancing the field, leading to the current position where clinicians are well-equipped with knowledge and ancillary resources that have dramatically improved specificity and sensitivity for the diagnosis of PD and its main differential diagnoses. Finally, it is foreseeable that additional layers of challenges and complexity will soon be triggered by the use of artificial intelligence and machine learning models in the context of the diagnosis, prediction, treatment, and prognosis of PD.

### Authors' Contributions

RPM: conceptualization, formal analysis, project, writing – original draft, writing – review & editing; vt - conceptualization, formal analysis, project, writing – original draft, writing – review & editing; JLP: conceptualization, formal analysis, project, writing – original draft, writing – review & editing; LSM: conceptualization, formal analysis, project, writing – original draft, writing – review & editing.

### Conflict of interest

There is no conflict of interest to declare.

### References

- 1 Parkinson J. An essay on the shaking palsy. 1817. *J Neuropsychiatry Clin Neurosci* 2002;14(02):223–236, discussion 222
- 2 Duvoisin RC. A brief history of parkinsonism. *Neurol Clin* 1992;10(02):301–316
- 3 Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. *Cold Spring Harb Perspect Med* 2011;1(01):a008862
- 4 Pearce JM. Aspects of the history of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1989;Suppl:6–10
- 5 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17(05):427–442
- 6 Quinn N. Multiple system atrophy—the nature of the beast. *J Neurol Neurosurg Psychiatry* 1989;Suppl:78–89
- 7 Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. *Trans Am Neurol Assoc* 1967;92:23–26
- 8 Steele JC, Richardson JC, Olszewski J. Progressive Supranuclear Palsy. A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia. *Arch Neurol* 1964;10:333–359
- 9 Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. *J Am Geriatr Soc* 1969;17(06):557–575



- 10 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1988;51(06):745–752
- 11 Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1991;54(05):388–396
- 12 Yahr MD, Duvoisin RC, Scheer MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. *Arch Neurol* 1969;21(04):343–354
- 13 Koller WC. The diagnosis of Parkinson's disease. *Arch Intern Med* 1984;144(11):2146–2147
- 14 Gibb WR. Accuracy in the clinical diagnosis of parkinsonian syndromes. *Postgrad Med J* 1988;64(751):345–351
- 15 Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. *Neuropathol Appl Neurobiol* 1989;15(01):27–44
- 16 Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. *Arch Neurol* 1960;2:511–527
- 17 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. *Neurology* 2001;57(08):1497–1499
- 18 Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 1997;276(5321):2045–2047
- 19 Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 2004;44(04):601–607
- 20 Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 2004;44(04):595–600
- 21 Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. *Mov Disord* 2006;21(12):2062–2067
- 22 Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. *Neurology* 1983;33(07):943–946
- 23 Hokusui S, Yasuda T, Yanagi T, et al. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. *J Auton Nerv Syst* 1994;49(01):81–84
- 24 Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. *Mov Disord* 2000;15(03):503–510
- 25 Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30(12):1591–1601
- 26 Berg D, Adler CH, Bloem BR, et al. Movement disorder society criteria for clinically established early Parkinson's disease. *Mov Disord* 2018;33(10):1643–1646
- 27 Munhoz RP, Werneck LC, Teive HA. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. *Clin Neurol Neurosurg* 2010;112(05):431–435
- 28 Munhoz RP, Bertucci Filho D, Teive HA. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype. *Neurol Sci* 2017;38(02):319–324
- 29 Höglinger GU, Respondek G, Stamelou M, et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord* 2017;32(06):853–864. Doi: 10.1002/mds.26987
- 30 Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. *Mov Disord* 2022;37(06):1131–1148
- 31 Yamada M, Komatsu J, Nakamura K, et al. Diagnostic Criteria for Dementia with Lewy Bodies: Updates and Future Directions. *J Mov Disord* 2020;13(01):1–10
- 32 Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. *Neurology* 2013;80(05):496–503. Doi: 10.1212/WNL.0b013e31827f0fd1
- 33 Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003;24(02):197–211
- 34 Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. *Mov Disord* 2012;27(05):617–626
- 35 Munhoz RP, Moro A, Silveira-Moriyama L, Teive HA. Non-motor signs in Parkinson's disease: a review. *Arq Neuropsiquiatr* 2015;73(05):454–462
- 36 Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1992;55(02):138–142
- 37 Saifee T, Lees AJ, Silveira-Moriyama L. Olfactory function in Parkinson's disease in ON versus OFF states. *J Neurol Neurosurg Psychiatry* 2010;81(11):1293–1295
- 38 Bohnen NI, Müller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. *Brain* 2010;133(Pt 6):1747–1754
- 39 Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann Neurol* 2012;72(06):893–901
- 40 Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. *Sleep* 2002;25(02):120–138
- 41 Postuma RB, Montplaisir J. Predicting Parkinson's disease - why, when, and how? *Parkinsonism Relat Disord* 2009;15(Suppl 3):S105–S109
- 42 American Academy of Sleep Medicine. ICSD - International classification of sleep disorders: diagnostic and coding manual. Westchester: American Sleep Disorders Association; 1990
- 43 Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *Mov Disord* 2012;27(07):913–916
- 44 Postuma RB, Gagnon JF, Montplaisir J. Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: the past 10 years. *Sleep Med* 2013;14(08):763–767
- 45 Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. *Brain* 2019;142(03):744–759
- 46 Munhoz RP, Teive HA. REM sleep behaviour disorder: how useful is it for the differential diagnosis of parkinsonism? *Clin Neurol Neurosurg* 2014;127:71–74
- 47 Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. *Curr Opin Psychiatry* 2012;25(06):468–472
- 48 Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. *Mov Disord* 2003;18(04):414–418
- 49 Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. *Acta Neurol Scand* 2006;113(04):211–220
- 50 Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* 2001;57(03):456–462
- 51 Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson's disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. *J Neurol Sci* 2012;313(1-2):57–63
- 52 Munhoz RP, Ribas CB. Body mass index in Parkinson's disease. *Parkinsonism Relat Disord* 2005;11(06):407, author reply 409
- 53 Cheshire WP Jr, Wszolek ZK. Body mass index is reduced early in Parkinson's disease. *Parkinsonism Relat Disord* 2005;11(01):35–38

- 54 Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Weight loss in Parkinson's disease. *Ann Neurol* 2003;53(05):676–679
- 55 Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. *Curr Opin Neurol* 2014;27(04):434–441
- 56 Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease. *Clin Med (Lond)* 2016;16(04):371–375
- 57 Meijer FJA, Goraj B, Bloem BR, Esselink RAJ. Clinical Application of Brain MRI in the Diagnostic Work-up of Parkinsonism. *J Parkinsons Dis* 2017;7(02):211–217
- 58 Weng YH, Yen TC, Chen MC, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. *J Nucl Med* 2004;45(03):393–401
- 59 Arjona M, Toldo JMP, Queiroz NC, et al. A Real-World Study of Cerebral 99mTc-TRODAT-1 Single-Photon Emission Computed Tomography (SPECT) Imaging of the Dopamine Transporter in Patients with Parkinson Disease from a Tertiary Hospital in Brazil. *Med Sci Monit* 2020;26:e925130
- 60 Pavese N, Tai YF. Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. *Mov Disord Clin Pract (Hoboken)* 2018;5(02):131–140
- 61 Belezia AB, Marussi VH, Yared J, et al. PET-CT imaging in a patient with progressive supranuclear palsy. *Arq Neuropsiquiatr* 2015;73(04):364–365
- 62 Bor-Seng-Shu E, Pedroso JL, Felicio AC, et al. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study. *Parkinsonism Relat Disord* 2014;20(05):477–481
- 63 Gasser T. Genetic testing for Parkinson's disease in clinical practice. *J Neural Transm (Vienna)* 2023;130(06):777–782
- 64 Saunders-Pullman R, Raymond D, Ortega RA, et al. International Genetic Testing and Counseling Practices for Parkinson's Disease. *Mov Disord* 2023;38(08):1527–1535
- 65 Aguiar Pde C, Lessa PS, Godeiro C Jr, et al. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. *Mov Disord* 2008;23(09):1228–1233
- 66 Munhoz RP, Wakutani Y, Marras C, et al. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. *Mov Disord* 2008;23(02):290–294
- 67 Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol* 2019;18(06):573–586